Are Mounjaro injections safe? What the clinical evidence says

What the licensed trial programme found about safety

The SURMOUNT-1 trial, published in the New England Journal of Medicine, randomised 2,539 adults with obesity across 72 weeks and gathered detailed safety data alongside the efficacy results. Across the SURMOUNT programme, tirzepatide's side-effect pattern was consistent: gastrointestinal events were the most reported, with nausea leading the list, followed by diarrhoea, constipation, vomiting and indigestion. The majority of these events were mild or moderate in severity, and discontinuation rates due to side effects were low relative to the weight-loss outcomes recorded. That evidence base underpins NICE's appraisal of tirzepatide, published in December 2024 and described at NICE TA1026, which accepted the safety profile as reasonable for adults who meet the licensed criteria.

Because Mounjaro carries the Black Triangle designation, Eli Lilly and the MHRA continue to collect post-marketing data. That is not a warning, it is standard practice for newer medicines and means the safety picture is actively updated rather than fixed at the point of approval. You can read the current patient-level summary on the NHS tirzepatide page.

The practical implication is straightforward: Mounjaro's safety is not in question when used as prescribed. The risks are real but manageable with clinical oversight, which is exactly why it is a prescription-only medicine.

Side effects to expect, and how to tell normal from not

Most people who start Mounjaro notice some digestive disruption. The classic pattern runs: queasiness around the day of injection, possibly loose stools or constipation in the days after, then gradual settling. That pattern is particularly common in the first four weeks and whenever the prescriber moves the dose up. Eating smaller portions, staying hydrated and avoiding fatty or heavily spiced food around injection day tends to help. A fuller guide to managing the Mounjaro injection experience covers these practical steps in more detail.

Less common but documented effects include headache, dizziness, fatigue and injection-site reactions, redness or a small lump where the pen was used. Rotating sites between the abdomen, thigh and upper arm on a regular basis reduces local reactions, and if you have wondered whether Mounjaro injections are painful, that page covers what to expect and how site rotation helps. For the full contraindication list and the exact storage window for the pen, the definitive reference is the Mounjaro SmPC on the electronic Medicines Compendium, always read the patient information leaflet supplied with your pen.

Women taking oral contraceptives should be aware that tirzepatide slows gastric emptying, which can reduce absorption of the pill. For the first four weeks of treatment and for four weeks after any dose increase, a non-oral method such as condoms is recommended alongside the pill, your prescriber will flag this at consultation. If you use HRT, a patch or gel may be preferable to an oral tablet while on Mounjaro; again, something to discuss at the same time.

When to get medical help, and what counts as urgent

Most side effects do not need emergency attention, but some do. The MHRA's January 2026 Drug Safety Update highlighted acute pancreatitis as a known, infrequent but serious risk with GLP-1 medicines: the key symptom is severe, persistent abdominal pain that may spread through to the back, with or without vomiting. If that describes what you are experiencing, stop the injection and seek urgent medical care, call 111 or go to A&E if the pain is severe.

Other situations that warrant prompt contact with a healthcare professional: signs of a serious allergic reaction (swelling of the face, lips or throat, difficulty breathing), significant dehydration from persistent vomiting or diarrhoea, gallbladder pain (sharp pain in the upper right abdomen, especially after eating), sudden changes in vision, or new or worsening low mood. If you experience any of these, contact your GP, call 111, or reach our aftercare team through the contact page, our clinical support runs seven days a week.

Suspected side effects can and should be reported directly to the MHRA via the Yellow Card scheme. This reporting is how post-market safety signals are detected; it matters even for symptoms that seem minor.

Who should not use Mounjaro, and how suitability is assessed

Mounjaro is not suitable for everyone. Pregnancy, breastfeeding and trying to conceive are all situations where it should not be used; nor is it licensed for anyone under 18. A personal or close family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 is a contraindication. Active or recent pancreatitis, and certain gastrointestinal conditions, require careful review. These are not edge-case concerns, they are assessed at every consultation because they change the clinical picture entirely.

At nume, every consultation is read by a real prescriber. A named clinician, not a decision tree, reviews your answers and medical history before any prescription is issued. If you are transferring from another provider or requesting a dose increase, we ask for evidence as part of that review. You can read more about what Mounjaro injections are and how they work, or explore our broader weight-loss treatment options if you are still weighing up which medicine fits your situation, including whether Mounjaro injection is safe for weight loss in your specific circumstances. Our clinical team oversees all prescribing decisions.

Worth noting: if you are planning surgery, even a routine procedure, tell your anaesthetist and surgical team that you are taking Mounjaro. Gastric emptying is slowed, which affects anaesthetic risk assessment. Plan ahead, particularly if you have a procedure booked around a bank holiday or are due to travel, since timing your last dose matters and your prescriber needs to advise on the interval, and our page on how the Mounjaro injection works explains the dosing schedule in full.